ML-007/muscarinic antagonist (MapLight Therapeutics)

N/A

Report date: 2026/05/20 20:02:01

NME

Base Information

Drug NameML-007/muscarinic antagonist (MapLight Therapeutics)

Drug Alias NameML-007/muscarinic antagonist combination tablet (MapLight Therapeutics)ML-007C-MAML-007/PAC

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionMuscarinic acetylcholine receptor M1 agonistsMuscarinic acetylcholine receptor M4 agonistsMuscarinic acetylcholine receptor antagonists

TargetsMuscarinic acetylcholine receptor M1Muscarinic acetylcholine receptor M4Muscarinic acetylcholine receptor

Therapy Area/IndicationsSchizophreniaAlzheimer DiseaseNervous System Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCzechiaBulgariaCanada +[8]

CombinationsYes

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesMapLight Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesMapLight Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsSchizophreniaAlzheimer Disease

Inactive IndicationsNervous System Diseases

Other Information

ATC CodeN/A